Search | Clinical Trials Finder

Conditions: Aging, Mild Cognitive Impairment, Hypertension
Interventions: bpMedManage; Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 60 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Tucson, Arizona • Champaign, Illinois

Conditions: Alcohol Use Disorder, Mild Traumatic Brain Injury
Interventions: Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 22 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Hines, Illinois

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSV MAT vaccine, dTpa vaccine; Combination Product
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 9 Years to 49 Years · Female only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Miami, Florida • Beaumont, Texas

Conditions: HIV Infections, Substance Use Disorders, Mental Health Disorder, Addiction, Opioid Use, Drug Use
Interventions: Collaborative Care Model; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Infant, Extremely Premature, Acute Lung Injury, Chronic Lung Disease of Prematurity, Budesonide
Interventions: Infants in the study group (S/B group) will receive surfactant 2.5 mls/kg and Budesonide 0.5 mg (1mL), Infants in the control group (S/P group) receive placebo (Normal saline 1mL); Drug
Lead sponsor: University of Arizona; Other
Eligibility: Up to 18 Hours
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Obesity
Interventions: Behavioral Treatment, Placebo, Phentermine 15 MG; Behavioral · Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 21 Years to 70 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Idiopathic Thrombocytopenic Purpura
Interventions: Eltrombopag, Avatrombopag, Standard of care; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Watertown, South Dakota

Conditions: Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Interventions: NT 201, Placebo; Drug
Lead sponsor: Merz North America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 12
States / cities: Encino, California • Newport Beach, California • San Diego, California + 7 more

Conditions: Schizophrenia and Related Disorders
Interventions: There is no intervention; Other
Lead sponsor: Northwell Health; Other
Eligibility: 15 Years to 40 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Glen Oaks, New York

Conditions: Parent-Child Relations, Child Maltreatment
Interventions: PriCARE/CARIÑO; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Months to 99 Years
Enrollment: 1,932 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Philadelphia, Pennsylvania

Conditions: Peripheral Arterial Disease
Interventions: Supervised Exercise, Vascular Assessment; Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 50 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Laparotomy, Dehiscence Wound, Surgical Site Infections, Trauma Abdomen, Emergency General Surgery
Interventions: triclosan-coated barbed suture, triclosan-coated non-barbed suture, Non-coated non-barbed suture; Device
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 100 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Treatment of Partial Thickness Burns
Interventions: Dehydrated Human Amnion/Chorion Membrane, Mepilex Ag; Other · Device
Lead sponsor: MiMedx Group, Inc.; Industry
Eligibility: 12 Months to 70 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 6
States / cities: Phoenix, Arizona • Los Angeles, California • San Diego, California + 3 more

Conditions: Aged, Frail Elderly
Interventions: Everyday Competence Assessment and Planning for Community Transitions; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Providence, Rhode Island • Houston, Texas

Conditions: Thyroid Cancer, Thyroid Carcinoma, Metastatic Thyroid Cancer, Follicular Thyroid Cancer, Unresectable Thyroid Gland Carcinoma, Papillary Thyroid Cancer
Interventions: Selpercatinib, Sodium Iodine I-131, rhTSH; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 12 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Tampa, Florida • Boston, Massachusetts + 3 more

Conditions: Pediatric Cancer, Predisposition, Genetic
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 8 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Prostate Cancer, Prostate Cancer Metastatic, Prostate Adenocarcinoma
Interventions: Relugolix Pill, Ritonavir, Itraconazole; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Autism Spectrum Disorder
Interventions: Parent-based Crisis Prevention Institute (CPI) physical management training program (P-CPI); Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 5 Years to 12 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Lexington, Massachusetts

Conditions: Obesity
Interventions: Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion, Phentermine; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hypertension, Diabetes Type 2
Interventions: Sitagliptin (DPP4 inhibitor), Substance P,, bradykinin, enalaprilat (ACE inhibitor), Glucagon-like peptide 1, brain natriuretic peptide; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Total Knee Arthoplasty
Interventions: total knee arthroplasty, Tobramycin, Gentamicin, Antibiotic cement spacer; Procedure · Drug · Device
Lead sponsor: Rothman Institute Orthopaedics; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Triple Negative Breast Cancer, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Biopsy-proven, Positive Lymph Node(s)
Interventions: Radiation Therapy Boost, Pembrolizumab, Paclitaxel, Carboplatin, Cyclophosphamide, Doxorubicin, Capecitabine; Radiation · Drug
Lead sponsor: Laura M. Spring, MD; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 10
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Boston, Massachusetts + 6 more

Conditions: Rheumatoid Arthritis
Interventions: Cognitive Behavior Therapy for Pain (CBT-P), Mindfulness Meditation for Emotion Regulation (MM-ER), Rheumatoid arthritis education; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 21 Years to 75 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Autism Spectrum Disorder, Autism
Interventions: Pivotal Response Treatment Program (PRT-P); Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 2 Years to 4 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Stanford, California

Search by objective public record fields.

bpMedManage: Digital Technology to Support Adherence to Hypertension Medications

rTMS Target Identification for Functional Disability in AUD+mTBI

A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age

Peer Supported Collaborative Care Mental Health and Substance Use Disorder Care

Intra-tracheal Instillation of Budesonide to Prevent Chronic Lung Disease

Use of Medication to Improve Weight Loss in Suboptimal Early Responders to Behavioral Treatment

A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)

Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines

Linguistic Predictors of Outcomes in Psychosis

Child-Adult Relationship Enhancement in Primary Care (PriCARE) / Criando Niños Con CARIÑO (CARIÑO)

The Impact of Branched-Chain Amino Acid Metabolism on Limb Dysfunction in PAD

Barbed Suture vs Non-Barbed Closure for Emergency Exploratory Laparotomy RCT

Dehydrated Human Amnion Chorion Membrane (dHACM) vs. Control in the Treatment of Partial Thickness Burns.

VA Community Living Centers to Home

Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

Psychosocial Impact of Disclosing Cancer Predisposition Genetic Testing Results During Childhood

A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients

CPI Training for Parents of Children With ASD

Individualized Obesity Pharmacotherapy

Pharmacogenetics of Ace Inhibitor-Associated Angioedema

Antibiotic Loaded Cement After TKA

Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)

Cognitive Behavioral Therapy Treatments for Adults With Rheumatoid Arthritis (The SARA Study)

Neuroimaging Predictors of Improvement to Pivotal Response Treatment (PRT) in Young Children With Autism